UTMD on Nasdaq

UTAH MEDICAL PRODUCTS INC

UTAH MEDICAL PRODUCTS INC is an American surgical and medical instruments and apparatus company.2 It is headquartered in Midvale, United States.2 Its shares trade on Nasdaq under the symbol UTMD.2

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with INTERPACE BIOSCIENCES, INC., RETRACTABLE TECHNOLOGIES INC or Cytosorbents, or pick any stock.

  • TickerUTMD on Nasdaq2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersMidvale, United States2
  • Incorporated inUT3
  • Business address7043 S 300 West, Midvale, Ut 840703
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formProfit Corporation2
  • LEI5493002R27BBGV8DID602
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Kevin L Cornwell, 84047 Midvale, United States2
  • Registered withUtah Division of Corporations & Commercial Code (Department of Commerce), 696062-01422

See how the biggest companies compare on our leaderboards

Currency amounts throughout this report are in thousands except per-share amounts and where noted.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

57.1%Gross margin6
29.6%Operating margin6
29.3%Net margin6
-5.8%Revenue growth, 20256
9.5%Return on equity6
0.00×Debt to equity6
$14.3MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

Global brought in 71% of the revenue UTAH MEDICAL PRODUCTS INC broke down this way in fiscal 2025.

  1. Global$38.5M671%down 6% from 2024
  2. OUS$15.8M629%down 10% from 2024
Regions by year
Regions202320242025
Global$50.2M$40.9M$38.5M
OUS$22.0M$17.5M$15.8M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue43¢$16.5M
  • Research and development2¢$668.0K
  • Other costs19¢$7.2M
  • Income tax7¢$2.8M
  • Profit29¢$11.3M

Out of $38.5M in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending3¢$371.0K
  • Dividends paid27¢$4.0M
  • Share buybacks57¢$8.4M
  • Kept or used elsewhere13¢$2.0M

Out of $14.7M of cash from operations.6

Financial statements

Revenue789106$38.5M in 2025−18% since 2019
0$20.0M$40.0M$60.0M2019: $46.9M$46.9M20192020: $42.2M$42.2M2020−10%2021: $49.1M$49.1M2021+16%2022: $52.3M$52.3M2022+7%2023: $50.2M$50.2M2023−4%2024: $40.9M$40.9M2024−19%2025: $38.5M$38.5M2025−6%
Gross profit789106$22.0M in 2025−25% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $29.5M$29.5M20192020: $25.5M$25.5M2020−13%2021: $30.9M$30.9M2021+21%2022: $32.2M$32.2M2022+4%2023: $30.0M$30.0M2023−7%2024: $24.1M$24.1M2024−20%2025: $22.0M$22.0M2025−9%
Operating income789106$11.4M in 2025−35% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $17.6M$17.6M20192020: $13.7M$13.7M2020−22%2021: $18.9M$18.9M2021+38%2022: $19.8M$19.8M2022+5%2023: $16.8M$16.8M2023−15%2024: $13.6M$13.6M2024−19%2025: $11.4M$11.4M2025−16%
Net income789106$11.3M in 2025−23% since 2019
0$5.0M$10.0M$15.0M$20.0M2019: $14.7M$14.7M20192020: $10.8M$10.8M2020−27%2021: $14.8M$14.8M2021+37%2022: $16.5M$16.5M2022+11%2023: $16.6M$16.6M2023+1%2024: $13.9M$13.9M2024−17%2025: $11.3M$11.3M2025−19%

Every line of the income statement as filed: the last 3 fiscal years (annual) or 12 quarters (quarterly), latest first.6

Period ending2025-12-312024-12-312023-12-31
Sales, net (notes 1, 3, 9 and 11)$38.5M$40.9M$50.2M
Cost of goods sold$16.5M$16.8M$20.2M
Gross profit$22.0M$24.1M$30.0M
Sales and marketing$2.1M$1.9M$1.7M
Research and development$668.0K$813.0K$560.0K
General and administrative$7.9M$7.8M$11.0M
Operating income$11.4M$13.6M$16.8M
Dividend and interest income$2.8M$3.4M$3.0M
Royalty income (note 12)$20.0K$15.0K$20.0K
Other, net-$120.0K-$174.0K$256.0K
Income before provision for income taxes$14.1M$16.8M$20.1M
Provision for income taxes (note 7)$2.8M$2.9M$3.5M
Net income$11.3M$13.9M$16.6M
Earnings per common share (basic) (note 1)$3.48$3.96$4.58
Earnings per common share (diluted)$3.48$3.96$4.57
Foreign currency translation net of taxes of $0 in all periods$2.5M-$1.2M$1.4M
Total comprehensive income$13.8M$12.6M$18.0M
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax$0$0

Compare UTAH MEDICAL PRODUCTS INC with another company

Corporate structure

UTAH MEDICAL PRODUCTS INC sits at the top of its group. 8 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of UTAH MEDICAL PRODUCTS INC

  • BRANDES INVESTMENT PARTNERS, LP Filed SCHEDULE 13G/A on UTAH MEDICAL PRODUCTS INC, latest Aug 14, 2026 (5 filings since May 14, 2025)
  • RENAISSANCE TECHNOLOGIES LLC Filed SCHEDULE 13G/A on UTAH MEDICAL PRODUCTS INC, latest Aug 13, 2026 (5 filings since Feb 11, 2022)
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on UTAH MEDICAL PRODUCTS INC, latest Mar 27, 2026 (5 filings since Feb 10, 2022)
  • DIMENSIONAL FUND ADVISORS LP Filed SCHEDULE 13G/A on UTAH MEDICAL PRODUCTS INC, latest Jul 15, 2025 (2 filings since Oct 31, 2024)
  • BlackRock Filed SCHEDULE 13G/A on UTAH MEDICAL PRODUCTS INC, latest Feb 5, 2025
  • FMR LLC Filed SCHEDULE 13G/A on UTAH MEDICAL PRODUCTS INC, latest Jan 8, 2025 (5 filings since Feb 9, 2022)
  • T. Rowe Price Investment Management, Inc. Filed SC 13G/A on UTAH MEDICAL PRODUCTS INC, latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on UTAH MEDICAL PRODUCTS INC, latest Aug 10, 2022 (3 filings since Feb 14, 2022)
  • UTAH MEDICAL PRODUCTS INC Midvale, Utah, United States
    • Abcorp Medical Subsidiary · Florida, United States
    • Columbia Medical & Surgical, Inc. Subsidiary · Oregon, United States
    • Femcare Australia Pty Ltd Subsidiary · Australia
    • Femcare Group Limited Subsidiary · United Kingdom
    • Femcare Limited Subsidiary · United Kingdom
    • Femcare N.Z. Ltd Subsidiary · New Zealand
    • Utah Medical Products Canada Inc. Subsidiary · Canada

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What UTAH MEDICAL PRODUCTS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$1.7M6 Dec 31, 2025$1.6M6 Dec 31, 2024+5.8%
Buildings and improvements$14.4M6 Dec 31, 2025$13.5M6 Dec 31, 2024+6.2%
Machinery and equipment$19.1M6 Dec 31, 2025$18.5M6 Dec 31, 2024+2.8%
Construction in progress$110.0K6 Dec 31, 2025$19.0K6 Dec 31, 2024+478.9%
Property and equipment, before depreciation$35.2M6 Dec 31, 2025$33.7M6 Dec 31, 2024+4.6%
Accumulated depreciation$25.3M6 Dec 31, 2025$23.9M6 Dec 31, 2024+5.9%
Property and equipment, net$9.9M6 Dec 31, 2025$9.8M6 Dec 31, 2024+1.5%
Operating-lease assets (leased space)$286.0K6 Dec 31, 2025$338.0K6 Dec 31, 2024−15.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$85.8M6 Dec 31, 2025$83.0M6 Dec 31, 2024+3.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$14.1M6 Dec 31, 2025$13.6M6 Dec 31, 2024+3.5%
Intangible assets, net (excluding goodwill)$840.0K6 Dec 31, 2025$2.9M6 Dec 31, 2024−70.7%
Finite-lived intangibles, gross$55.9M6 Dec 31, 2025$53.8M6 Dec 31, 2024+4.0%
Accumulated amortization$55.1M6 Dec 31, 2025$50.9M6 Dec 31, 2024+8.2%
Finite-lived intangibles, net$840.0K6 Dec 31, 2025$2.9M6 Dec 31, 2024−70.7%
Patents, net$2.2M6 Dec 31, 2025$2.2M6 Dec 31, 2024+0.5%
Customer relationships, net$9.6M6 Dec 31, 2025$9.0M6 Dec 31, 2024+7.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$7.9M6 Dec 31, 2025$8.8M6 Dec 31, 2024−10.0%
Raw materials$5.1M6 Dec 31, 2025$5.5M6 Dec 31, 2024−7.3%
Work in process$1.6M6 Dec 31, 2025$1.4M6 Dec 31, 2024+15.1%
Finished goods$1.2M6 Dec 31, 2025$1.9M6 Dec 31, 2024−36.1%

Properties, in its own words

Office and Manufacturing Facilities.

UTMD is a vertically-integrated manufacturing company. Capabilities include silicone and plastics-forming operations including injection molding, insert and over-molding, thermoforming and extrusion; sensor production; manual and automated assembly of mechanical, electrical and electronic components; parts printing; various testing modalities; advanced packaging in clean room conditions; and a machine shop for mold-making and fabrication of assembly tools and fixtures. Capabilities also include an R&D laboratory for both electronic and chemical processes, software development resources, communications and computer systems networked real time OUS, and administrative offices.

The rest of Item 2

UTMD owns all of its property and facilities with the exception of a long-term lease with 5 years remaining on one section of its Midvale parking lot. As of the beginning of 2026, the Company's operations were located in 105,000 square feet of facilities in Midvale, Utah, a 77,000 square foot facility in Athlone, County Westmeath, Ireland, a 38,600 square foot facility in Romsey, Hampshire, England, a 3,200 square foot facility in Castle Hill NSW, Australia, and a 4,700 square foot facility in Mississauga, Ontario, Canada. Manufacturing is currently carried out primarily in the Utah and Ireland facilities.

Item 2 of the 10-K filed Mar 27, 2026.5

Leadership

Who has led UTAH MEDICAL PRODUCTS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kevin L. Cornwell2006–2021

Chair

  1. Kevin L. Cornwell2006–2021

Chief financial officer

  1. Greg A. Leclaire2006
2010201520202025
Board members and other officers (9)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Abcorp Medical Florida4
  • Columbia Medical & Surgical, Inc. Oregon4
  • Femcare Australia Pty Ltd Australia4
  • Femcare Group Limited United Kingdom4
  • Femcare Limited United Kingdom4
  • Femcare N.Z. Ltd New Zealand4
  • Utah Medical Products Canada Inc. Canada4
  • Utah Medical Products Ltd. Bermuda4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Aug 31, 20268-K Regulation FD disclosure24
  2. Jul 23, 20268-K Results of operations25
  3. May 4, 20268-K Shareholder vote26
  4. Apr 23, 20268-K Results of operations27
  5. Jan 29, 20268-K Results of operations28
  6. Nov 4, 20258-K Executive or director change; Other events29
  7. Oct 23, 20258-K Results of operations30
  8. Jul 24, 20258-K Results of operations31
  9. May 5, 20258-K Shareholder vote32
  10. Apr 29, 20258-K Results of operations33
  11. Jan 28, 20258-K Results of operations34
  12. Nov 5, 20248-K Executive or director change; Other events35
  13. Jan 4, 2006New chief executive Kevin L. Cornwell becomes CEO14

Calendar

Coming up

  1. Oct 22, 2026Reports results for the quarter ending Sep/202636

When it reported results

  1. Jul 23, 2026Reported quarterly or annual results25
  2. Apr 23, 2026Reported quarterly or annual results27
  3. Jan 29, 2026Reported quarterly or annual results28
  4. Oct 23, 2025Reported quarterly or annual results30
  5. Jul 24, 2025Reported quarterly or annual results31
  6. Apr 29, 2025Reported quarterly or annual results33
  7. Jan 28, 2025Reported quarterly or annual results34
  8. Oct 29, 2024Reported quarterly or annual results37

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

135 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 32 major events, 30 insider forms, 31 large holders, 21 other. The latest 20:

  1. Oct 5, 2026SC TO-I/A SCHEDULE TO-I/A EDGAR
  2. Sep 29, 2026SC TO-I/A SCHEDULE TO-I/A EDGAR
  3. Sep 25, 2026SC TO-C SCHEDULE TO-C EDGAR
  4. Sep 24, 2026SC TO-C SCHEDULE TO-C EDGAR
  5. Sep 24, 2026SC 13E3 SC TO-I EDGAR
  6. Sep 17, 2026SC TO-C EDGAR
  7. Aug 31, 20268-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING EDGAR
  8. Aug 14, 2026SCHEDULE 13G/A EDGAR
  9. Aug 13, 2026SCHEDULE 13G/A EDGAR
  10. Aug 12, 202610-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING EDGAR
  11. Jul 23, 20268-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING EDGAR
  12. Jul 1, 20264 PRIMARY DOCUMENT EDGAR
  13. May 29, 20264 PRIMARY DOCUMENT EDGAR
  14. May 27, 2026SD UTAH MEDICAL FORM SD EDGAR
  15. May 14, 2026SCHEDULE 13G/A EDGAR
  16. May 12, 202610-Q UTAH MEDICAL PRODUCTS INC - FORM 10-Q SEC FILING EDGAR
  17. May 4, 20268-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING EDGAR
  18. Apr 23, 20268-K UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING EDGAR
  19. Apr 2, 2026DEF 14A PROXY STATEMENT EDGAR
  20. Mar 27, 202610-K UTAH MEDICAL PRODUCTS INC - FORM 10-K SEC FILING EDGAR

The 135 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 0 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 18, 2023RICHINS PAUL ODirectorSale700$93.47$65.4KForm 4
Nov 18, 2022RICHINS PAUL ODirectorSale449$90.81$40.8KForm 4
Nov 17, 2022RICHINS PAUL ODirectorSale161$90.00$14.5KForm 4
Nov 11, 2022RICHINS PAUL ODirectorSale40$92.50$3.7KForm 4
May 11, 2022PAYNE BARBARA ADirectorSale2,000$85.20$170.4KForm 4
Nov 24, 2021HOYER ERNST GDirectorSale4,900$126.41$619.4KForm 4
Nov 23, 2021HOYER ERNST GDirectorSale100$125.01$12.5KForm 4
Nov 18, 2021PAYNE BARBARA ADirectorSale1,249$111.06$138.7KForm 4
Nov 17, 2021PAYNE BARBARA ADirectorSale751$111.06$83.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Kevin L. Cornwell$87.0K$341.7K46
2025Brian L. Koopman$153.2K$179.1K46
2024Chairman & CEO$156.0K$455.1K46
2024Principal Financial Officer$140.1K$167.8K46
2023Chairman & CEO$152.0K$510.6K46
2023Principal Financial Officer$131.8K$165.3K46

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Brandes Investment Partners, LP475,158$32.8M0.2%+25,879
BlackRock, Inc.203,690$14.1M0.0%+16,041
Dimensional Fund Advisors LP198,817$13.7M0.0%+909
Renaissance Technologies LLC175,814$12.1M0.0%−8,300
Vanguard Capital Management LLC134,535$9.3M0.0%−4,025
Geode Capital Management, LLC108,048$7.5M0.0%−12,049
Minerva Advisors LLC93,615$6.5M4.1%No change
Hotchkis & Wiley Capital Management LLC85,231$5.9M0.0%−3,900
Rice Hall James & Associates, LLC71,363$4.9M0.2%+3,481
Morgan Stanley69,671$4.8M0.0%+20,870
State Street Corp63,937$4.4M0.0%−465
Quantinno Capital Management LP43,074$3.0M0.0%+13,233
UBS Group AG34,369$2.4M0.0%−2,547
Bank of New York Mellon Corp34,263$2.4M0.0%+2,181
Northern Trust Corp30,104$2.1M0.0%−188
Huber Capital Management LLC29,009$2.0M0.3%−6,906
Cardinal Capital Management27,094$1.9M0.2%+551
Everett Harris & Co /ca/23,933$1.7M0.0%−1,631
O'shaughnessy Asset Management, LLC21,683$1.5M0.0%+396
Segall Bryant & Hamill, LLC21,547$1.5M0.0%No change
Vanguard Portfolio Management LLC20,276$1.4M0.0%+2,839
Vanguard Fiduciary Trust Co20,014$1.4M0.0%+958
Bard Associates Inc18,455$1.3M0.3%+94
Fmr LLC18,068$1.2M0.0%+6
Aqr Capital Management LLC14,993$1.0M0.0%+4,722

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How UTAH MEDICAL PRODUCTS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARUTAH MEDICAL PRODUCTS INC1
  • CIK0000706698
  • Employer ID (EIN)87-03427345
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inUtah5
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address7043 S 300 West, Midvale, UT 840701
  • Mailing address7043 S 300 West, Midvale, UT 840471
  • Phone80152153011
  • Shares outstanding3,183,818 as of Aug 11, 202612
  • Public float$168.2M as of 5
  • AuditorHaynie & Company, Salt Lake City, Utah PCAOB ID 457; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceFeb 14, 19941
  • Filings844 in all: 4 (226), 8-K (212), 10-Q (95), SC 13G/A (89), DEF 14A (32), 10-K (31), SC 13G (18), CORRESP (17)1
    All 35 form types

    UPLOAD (17), SD (13), ARS (11), 8-K/A (10), SCHEDULE 13G/A (10), SC TO-I/A (9), 10-K/A (7), SC TO-C (7), 10-Q/A (4), 3 (4), SC 13E4/A (4), DEFA14A (3), S-3/A (3), S-8 (3), 144 (2), 4/A (2), 8-A12B/A (2), S-3 (2), SC TO-I (2), SCHEDULE 13G (2), 8-A12B (1), 8-A12G (1), EFFECT (1), PX14A6G (1), RW (1), SC 13E3 (1), SC 13E4 (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2026
    Quarterly report (10-Q) Aug 12, 2026
    Proxy statement (DEF 14A) Apr 2, 2026
    Latest 8-K (8-K) Aug 31, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, $0.01 par valueUTMDNASDAQ

From the cover page of the 10-K filed Mar 27, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

Legal proceedings

The Company may be a party from time to time in litigation incidental to its business. Presently, except for Filshie clip lawsuits, there is no litigation or threatened litigation where UTMD is a defendant. The Company expects that the outcome of the Filshie clip litigation will not be material to overall consolidated financial results.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46